Straits Times Index
3,262.45 +23.42 (+0.72%) Nikkei
27,518.25 +41.38 (+0.15%) Hang Seng
19,805.16 +237.47 (+1.21%) FTSE 100
7,471.77 +66.32 (+0.90%) BTC-USD
27,087.97 -711.21 (-2.56%) CMC Crypto 200
589.59 -17.86 (-2.94%)
Kyowa Kirin Co., Ltd. (KYKOF)
| Previous close | 20.87 |
| Open | 20.87 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.87 - 20.87 |
| 52-week range | 20.87 - 28.73 |
| Volume | |
| Avg. volume | 460 |
| Market cap | 11.217B |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | 26.02 |
| EPS (TTM) | 0.80 |
| Earnings date | N/A |
| Forward dividend & yield | 0.41 (1.84%) |
| Ex-dividend date | 29 Jun 2023 |
| 1y target est | N/A |
- Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob
- Business Wire
Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio
AACHEN, Germany & TOKYO, November 24, 2022--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic
- Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
SAN DIEGO & TOKYO, November 03, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational
